Loading…

Development of N‑(1-Adamantyl)benzamides as Novel Anti-Inflammatory Multitarget Agents Acting as Dual Modulators of the Cannabinoid CB2 Receptor and Fatty Acid Amide Hydrolase

Cannabinoid type 2 receptor (CB2R), belonging to the endocannabinoid system, is overexpressed in pathologies characterized by inflammation, and its activation counteracts inflammatory states. Fatty acid amide hydrolase (FAAH) is an enzyme responsible for the degradation of the main endocannabinoid a...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medicinal chemistry 2023-01, Vol.66 (1), p.235-250
Main Authors: Intranuovo, Francesca, Brunetti, Leonardo, DelRe, Pietro, Mangiatordi, Giuseppe Felice, Stefanachi, Angela, Laghezza, Antonio, Niso, Mauro, Leonetti, Francesco, Loiodice, Fulvio, Ligresti, Alessia, Kostrzewa, Magdalena, Brea, Jose, Loza, Maria Isabel, Sotelo, Eddy, Saviano, Michele, Colabufo, Nicola Antonio, Riganti, Chiara, Abate, Carmen, Contino, Marialessandra
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a348t-f369fbff044b387d8dc4103b99fb4efa3b02b0d9732707ce57f5cb28ce0720983
cites cdi_FETCH-LOGICAL-a348t-f369fbff044b387d8dc4103b99fb4efa3b02b0d9732707ce57f5cb28ce0720983
container_end_page 250
container_issue 1
container_start_page 235
container_title Journal of medicinal chemistry
container_volume 66
creator Intranuovo, Francesca
Brunetti, Leonardo
DelRe, Pietro
Mangiatordi, Giuseppe Felice
Stefanachi, Angela
Laghezza, Antonio
Niso, Mauro
Leonetti, Francesco
Loiodice, Fulvio
Ligresti, Alessia
Kostrzewa, Magdalena
Brea, Jose
Loza, Maria Isabel
Sotelo, Eddy
Saviano, Michele
Colabufo, Nicola Antonio
Riganti, Chiara
Abate, Carmen
Contino, Marialessandra
description Cannabinoid type 2 receptor (CB2R), belonging to the endocannabinoid system, is overexpressed in pathologies characterized by inflammation, and its activation counteracts inflammatory states. Fatty acid amide hydrolase (FAAH) is an enzyme responsible for the degradation of the main endocannabinoid anandamide; thus, the simultaneous CB2R activation and FAAH inhibition may be a synergistic anti-inflammatory strategy. Encouraged by principal component analysis (PCA) data identifying a wide chemical space shared by CB2R and FAAH ligands, we designed a small library of adamantyl-benzamides, as potential dual agents, CB2R agonists, and FAAH inhibitors. The new compounds were tested for their CB2R affinity/selectivity and CB2R and FAAH activity. Derivatives 13, 26, and 27, displaying the best pharmacodynamic profile as CB2R full agonists and FAAH inhibitors, decreased pro-inflammatory and increased anti-inflammatory cytokines production. Molecular docking simulations complemented the experimental findings by providing a molecular rationale behind the observed activities. These multitarget ligands constitute promising anti-inflammatory agents.
doi_str_mv 10.1021/acs.jmedchem.2c01084
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2757054448</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2757054448</sourcerecordid><originalsourceid>FETCH-LOGICAL-a348t-f369fbff044b387d8dc4103b99fb4efa3b02b0d9732707ce57f5cb28ce0720983</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhi1ERZfCGyDkYzlkO7GdTfYYtpRWaouE4Bw59nibyrGX2KkUTrwCj8Ir8SQ43W2PnEaa-f7_1-gn5F0OyxxYfiZVWN73qNUd9kumIIdKvCCLvGCQiQrES7IAYCxjK8aPyesQ7gGA54y_Isd8VQhW8dWC_DnHB7R-16OL1Bt6-_fX79M8q7XspYuT_dCi-yn7TmOgMtBbn2hau9hlV85Y2fcy-mGiN6ONXZTDFiOtt8kr0FrFzm1n0fkoLb3xerQzHOaYeId0I52Tbed8p-nmI6NfUeEuAVQ6TS9kjFPySLd6TqeXkx68lQHfkCMjbcC3h3lCvl98-ra5zK6_fL7a1NeZ5KKKmeGrtWmNASFaXpW60krkwNt12go0krfAWtDrkrMSSoVFaQrVskohlAzWFT8hp3vf3eB_jBhi03dBobXSoR9Dw8qihEIIMaNij6rBhzCgaXZD18thanJo5rKaVFbzVFZzKCvJ3h8SxjbdnkVP7SQA9sCj3I-DSw__3_MfYM-mxA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2757054448</pqid></control><display><type>article</type><title>Development of N‑(1-Adamantyl)benzamides as Novel Anti-Inflammatory Multitarget Agents Acting as Dual Modulators of the Cannabinoid CB2 Receptor and Fatty Acid Amide Hydrolase</title><source>American Chemical Society:Jisc Collections:American Chemical Society Read &amp; Publish Agreement 2022-2024 (Reading list)</source><creator>Intranuovo, Francesca ; Brunetti, Leonardo ; DelRe, Pietro ; Mangiatordi, Giuseppe Felice ; Stefanachi, Angela ; Laghezza, Antonio ; Niso, Mauro ; Leonetti, Francesco ; Loiodice, Fulvio ; Ligresti, Alessia ; Kostrzewa, Magdalena ; Brea, Jose ; Loza, Maria Isabel ; Sotelo, Eddy ; Saviano, Michele ; Colabufo, Nicola Antonio ; Riganti, Chiara ; Abate, Carmen ; Contino, Marialessandra</creator><creatorcontrib>Intranuovo, Francesca ; Brunetti, Leonardo ; DelRe, Pietro ; Mangiatordi, Giuseppe Felice ; Stefanachi, Angela ; Laghezza, Antonio ; Niso, Mauro ; Leonetti, Francesco ; Loiodice, Fulvio ; Ligresti, Alessia ; Kostrzewa, Magdalena ; Brea, Jose ; Loza, Maria Isabel ; Sotelo, Eddy ; Saviano, Michele ; Colabufo, Nicola Antonio ; Riganti, Chiara ; Abate, Carmen ; Contino, Marialessandra</creatorcontrib><description>Cannabinoid type 2 receptor (CB2R), belonging to the endocannabinoid system, is overexpressed in pathologies characterized by inflammation, and its activation counteracts inflammatory states. Fatty acid amide hydrolase (FAAH) is an enzyme responsible for the degradation of the main endocannabinoid anandamide; thus, the simultaneous CB2R activation and FAAH inhibition may be a synergistic anti-inflammatory strategy. Encouraged by principal component analysis (PCA) data identifying a wide chemical space shared by CB2R and FAAH ligands, we designed a small library of adamantyl-benzamides, as potential dual agents, CB2R agonists, and FAAH inhibitors. The new compounds were tested for their CB2R affinity/selectivity and CB2R and FAAH activity. Derivatives 13, 26, and 27, displaying the best pharmacodynamic profile as CB2R full agonists and FAAH inhibitors, decreased pro-inflammatory and increased anti-inflammatory cytokines production. Molecular docking simulations complemented the experimental findings by providing a molecular rationale behind the observed activities. These multitarget ligands constitute promising anti-inflammatory agents.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/acs.jmedchem.2c01084</identifier><identifier>PMID: 36542836</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Amidohydrolases ; Anti-Inflammatory Agents - pharmacology ; Benzamides - pharmacology ; Cannabinoid Receptor Agonists ; Cannabinoids ; Endocannabinoids - metabolism ; Molecular Docking Simulation ; Receptor, Cannabinoid, CB1 ; Receptor, Cannabinoid, CB2</subject><ispartof>Journal of medicinal chemistry, 2023-01, Vol.66 (1), p.235-250</ispartof><rights>2022 American Chemical Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a348t-f369fbff044b387d8dc4103b99fb4efa3b02b0d9732707ce57f5cb28ce0720983</citedby><cites>FETCH-LOGICAL-a348t-f369fbff044b387d8dc4103b99fb4efa3b02b0d9732707ce57f5cb28ce0720983</cites><orcidid>0000-0002-0713-3151 ; 0000-0001-9292-884X ; 0000-0003-3384-574X ; 0000-0001-9787-4836 ; 0000-0002-5523-1979 ; 0000-0003-4730-0863 ; 0000-0003-4042-2841 ; 0000-0003-1787-3900 ; 0000-0001-6221-6155 ; 0000-0002-9430-7972 ; 0000-0001-5571-2812 ; 0000-0001-5086-2459 ; 0000-0002-7787-6639 ; 0000-0001-5639-7746</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36542836$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Intranuovo, Francesca</creatorcontrib><creatorcontrib>Brunetti, Leonardo</creatorcontrib><creatorcontrib>DelRe, Pietro</creatorcontrib><creatorcontrib>Mangiatordi, Giuseppe Felice</creatorcontrib><creatorcontrib>Stefanachi, Angela</creatorcontrib><creatorcontrib>Laghezza, Antonio</creatorcontrib><creatorcontrib>Niso, Mauro</creatorcontrib><creatorcontrib>Leonetti, Francesco</creatorcontrib><creatorcontrib>Loiodice, Fulvio</creatorcontrib><creatorcontrib>Ligresti, Alessia</creatorcontrib><creatorcontrib>Kostrzewa, Magdalena</creatorcontrib><creatorcontrib>Brea, Jose</creatorcontrib><creatorcontrib>Loza, Maria Isabel</creatorcontrib><creatorcontrib>Sotelo, Eddy</creatorcontrib><creatorcontrib>Saviano, Michele</creatorcontrib><creatorcontrib>Colabufo, Nicola Antonio</creatorcontrib><creatorcontrib>Riganti, Chiara</creatorcontrib><creatorcontrib>Abate, Carmen</creatorcontrib><creatorcontrib>Contino, Marialessandra</creatorcontrib><title>Development of N‑(1-Adamantyl)benzamides as Novel Anti-Inflammatory Multitarget Agents Acting as Dual Modulators of the Cannabinoid CB2 Receptor and Fatty Acid Amide Hydrolase</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>Cannabinoid type 2 receptor (CB2R), belonging to the endocannabinoid system, is overexpressed in pathologies characterized by inflammation, and its activation counteracts inflammatory states. Fatty acid amide hydrolase (FAAH) is an enzyme responsible for the degradation of the main endocannabinoid anandamide; thus, the simultaneous CB2R activation and FAAH inhibition may be a synergistic anti-inflammatory strategy. Encouraged by principal component analysis (PCA) data identifying a wide chemical space shared by CB2R and FAAH ligands, we designed a small library of adamantyl-benzamides, as potential dual agents, CB2R agonists, and FAAH inhibitors. The new compounds were tested for their CB2R affinity/selectivity and CB2R and FAAH activity. Derivatives 13, 26, and 27, displaying the best pharmacodynamic profile as CB2R full agonists and FAAH inhibitors, decreased pro-inflammatory and increased anti-inflammatory cytokines production. Molecular docking simulations complemented the experimental findings by providing a molecular rationale behind the observed activities. These multitarget ligands constitute promising anti-inflammatory agents.</description><subject>Amidohydrolases</subject><subject>Anti-Inflammatory Agents - pharmacology</subject><subject>Benzamides - pharmacology</subject><subject>Cannabinoid Receptor Agonists</subject><subject>Cannabinoids</subject><subject>Endocannabinoids - metabolism</subject><subject>Molecular Docking Simulation</subject><subject>Receptor, Cannabinoid, CB1</subject><subject>Receptor, Cannabinoid, CB2</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kcFu1DAQhi1ERZfCGyDkYzlkO7GdTfYYtpRWaouE4Bw59nibyrGX2KkUTrwCj8Ir8SQ43W2PnEaa-f7_1-gn5F0OyxxYfiZVWN73qNUd9kumIIdKvCCLvGCQiQrES7IAYCxjK8aPyesQ7gGA54y_Isd8VQhW8dWC_DnHB7R-16OL1Bt6-_fX79M8q7XspYuT_dCi-yn7TmOgMtBbn2hau9hlV85Y2fcy-mGiN6ONXZTDFiOtt8kr0FrFzm1n0fkoLb3xerQzHOaYeId0I52Tbed8p-nmI6NfUeEuAVQ6TS9kjFPySLd6TqeXkx68lQHfkCMjbcC3h3lCvl98-ra5zK6_fL7a1NeZ5KKKmeGrtWmNASFaXpW60krkwNt12go0krfAWtDrkrMSSoVFaQrVskohlAzWFT8hp3vf3eB_jBhi03dBobXSoR9Dw8qihEIIMaNij6rBhzCgaXZD18thanJo5rKaVFbzVFZzKCvJ3h8SxjbdnkVP7SQA9sCj3I-DSw__3_MfYM-mxA</recordid><startdate>20230112</startdate><enddate>20230112</enddate><creator>Intranuovo, Francesca</creator><creator>Brunetti, Leonardo</creator><creator>DelRe, Pietro</creator><creator>Mangiatordi, Giuseppe Felice</creator><creator>Stefanachi, Angela</creator><creator>Laghezza, Antonio</creator><creator>Niso, Mauro</creator><creator>Leonetti, Francesco</creator><creator>Loiodice, Fulvio</creator><creator>Ligresti, Alessia</creator><creator>Kostrzewa, Magdalena</creator><creator>Brea, Jose</creator><creator>Loza, Maria Isabel</creator><creator>Sotelo, Eddy</creator><creator>Saviano, Michele</creator><creator>Colabufo, Nicola Antonio</creator><creator>Riganti, Chiara</creator><creator>Abate, Carmen</creator><creator>Contino, Marialessandra</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0713-3151</orcidid><orcidid>https://orcid.org/0000-0001-9292-884X</orcidid><orcidid>https://orcid.org/0000-0003-3384-574X</orcidid><orcidid>https://orcid.org/0000-0001-9787-4836</orcidid><orcidid>https://orcid.org/0000-0002-5523-1979</orcidid><orcidid>https://orcid.org/0000-0003-4730-0863</orcidid><orcidid>https://orcid.org/0000-0003-4042-2841</orcidid><orcidid>https://orcid.org/0000-0003-1787-3900</orcidid><orcidid>https://orcid.org/0000-0001-6221-6155</orcidid><orcidid>https://orcid.org/0000-0002-9430-7972</orcidid><orcidid>https://orcid.org/0000-0001-5571-2812</orcidid><orcidid>https://orcid.org/0000-0001-5086-2459</orcidid><orcidid>https://orcid.org/0000-0002-7787-6639</orcidid><orcidid>https://orcid.org/0000-0001-5639-7746</orcidid></search><sort><creationdate>20230112</creationdate><title>Development of N‑(1-Adamantyl)benzamides as Novel Anti-Inflammatory Multitarget Agents Acting as Dual Modulators of the Cannabinoid CB2 Receptor and Fatty Acid Amide Hydrolase</title><author>Intranuovo, Francesca ; Brunetti, Leonardo ; DelRe, Pietro ; Mangiatordi, Giuseppe Felice ; Stefanachi, Angela ; Laghezza, Antonio ; Niso, Mauro ; Leonetti, Francesco ; Loiodice, Fulvio ; Ligresti, Alessia ; Kostrzewa, Magdalena ; Brea, Jose ; Loza, Maria Isabel ; Sotelo, Eddy ; Saviano, Michele ; Colabufo, Nicola Antonio ; Riganti, Chiara ; Abate, Carmen ; Contino, Marialessandra</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a348t-f369fbff044b387d8dc4103b99fb4efa3b02b0d9732707ce57f5cb28ce0720983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Amidohydrolases</topic><topic>Anti-Inflammatory Agents - pharmacology</topic><topic>Benzamides - pharmacology</topic><topic>Cannabinoid Receptor Agonists</topic><topic>Cannabinoids</topic><topic>Endocannabinoids - metabolism</topic><topic>Molecular Docking Simulation</topic><topic>Receptor, Cannabinoid, CB1</topic><topic>Receptor, Cannabinoid, CB2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Intranuovo, Francesca</creatorcontrib><creatorcontrib>Brunetti, Leonardo</creatorcontrib><creatorcontrib>DelRe, Pietro</creatorcontrib><creatorcontrib>Mangiatordi, Giuseppe Felice</creatorcontrib><creatorcontrib>Stefanachi, Angela</creatorcontrib><creatorcontrib>Laghezza, Antonio</creatorcontrib><creatorcontrib>Niso, Mauro</creatorcontrib><creatorcontrib>Leonetti, Francesco</creatorcontrib><creatorcontrib>Loiodice, Fulvio</creatorcontrib><creatorcontrib>Ligresti, Alessia</creatorcontrib><creatorcontrib>Kostrzewa, Magdalena</creatorcontrib><creatorcontrib>Brea, Jose</creatorcontrib><creatorcontrib>Loza, Maria Isabel</creatorcontrib><creatorcontrib>Sotelo, Eddy</creatorcontrib><creatorcontrib>Saviano, Michele</creatorcontrib><creatorcontrib>Colabufo, Nicola Antonio</creatorcontrib><creatorcontrib>Riganti, Chiara</creatorcontrib><creatorcontrib>Abate, Carmen</creatorcontrib><creatorcontrib>Contino, Marialessandra</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Intranuovo, Francesca</au><au>Brunetti, Leonardo</au><au>DelRe, Pietro</au><au>Mangiatordi, Giuseppe Felice</au><au>Stefanachi, Angela</au><au>Laghezza, Antonio</au><au>Niso, Mauro</au><au>Leonetti, Francesco</au><au>Loiodice, Fulvio</au><au>Ligresti, Alessia</au><au>Kostrzewa, Magdalena</au><au>Brea, Jose</au><au>Loza, Maria Isabel</au><au>Sotelo, Eddy</au><au>Saviano, Michele</au><au>Colabufo, Nicola Antonio</au><au>Riganti, Chiara</au><au>Abate, Carmen</au><au>Contino, Marialessandra</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of N‑(1-Adamantyl)benzamides as Novel Anti-Inflammatory Multitarget Agents Acting as Dual Modulators of the Cannabinoid CB2 Receptor and Fatty Acid Amide Hydrolase</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>2023-01-12</date><risdate>2023</risdate><volume>66</volume><issue>1</issue><spage>235</spage><epage>250</epage><pages>235-250</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><abstract>Cannabinoid type 2 receptor (CB2R), belonging to the endocannabinoid system, is overexpressed in pathologies characterized by inflammation, and its activation counteracts inflammatory states. Fatty acid amide hydrolase (FAAH) is an enzyme responsible for the degradation of the main endocannabinoid anandamide; thus, the simultaneous CB2R activation and FAAH inhibition may be a synergistic anti-inflammatory strategy. Encouraged by principal component analysis (PCA) data identifying a wide chemical space shared by CB2R and FAAH ligands, we designed a small library of adamantyl-benzamides, as potential dual agents, CB2R agonists, and FAAH inhibitors. The new compounds were tested for their CB2R affinity/selectivity and CB2R and FAAH activity. Derivatives 13, 26, and 27, displaying the best pharmacodynamic profile as CB2R full agonists and FAAH inhibitors, decreased pro-inflammatory and increased anti-inflammatory cytokines production. Molecular docking simulations complemented the experimental findings by providing a molecular rationale behind the observed activities. These multitarget ligands constitute promising anti-inflammatory agents.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>36542836</pmid><doi>10.1021/acs.jmedchem.2c01084</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0002-0713-3151</orcidid><orcidid>https://orcid.org/0000-0001-9292-884X</orcidid><orcidid>https://orcid.org/0000-0003-3384-574X</orcidid><orcidid>https://orcid.org/0000-0001-9787-4836</orcidid><orcidid>https://orcid.org/0000-0002-5523-1979</orcidid><orcidid>https://orcid.org/0000-0003-4730-0863</orcidid><orcidid>https://orcid.org/0000-0003-4042-2841</orcidid><orcidid>https://orcid.org/0000-0003-1787-3900</orcidid><orcidid>https://orcid.org/0000-0001-6221-6155</orcidid><orcidid>https://orcid.org/0000-0002-9430-7972</orcidid><orcidid>https://orcid.org/0000-0001-5571-2812</orcidid><orcidid>https://orcid.org/0000-0001-5086-2459</orcidid><orcidid>https://orcid.org/0000-0002-7787-6639</orcidid><orcidid>https://orcid.org/0000-0001-5639-7746</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0022-2623
ispartof Journal of medicinal chemistry, 2023-01, Vol.66 (1), p.235-250
issn 0022-2623
1520-4804
language eng
recordid cdi_proquest_miscellaneous_2757054448
source American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list)
subjects Amidohydrolases
Anti-Inflammatory Agents - pharmacology
Benzamides - pharmacology
Cannabinoid Receptor Agonists
Cannabinoids
Endocannabinoids - metabolism
Molecular Docking Simulation
Receptor, Cannabinoid, CB1
Receptor, Cannabinoid, CB2
title Development of N‑(1-Adamantyl)benzamides as Novel Anti-Inflammatory Multitarget Agents Acting as Dual Modulators of the Cannabinoid CB2 Receptor and Fatty Acid Amide Hydrolase
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T19%3A47%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20N%E2%80%91(1-Adamantyl)benzamides%20as%20Novel%20Anti-Inflammatory%20Multitarget%20Agents%20Acting%20as%20Dual%20Modulators%20of%20the%20Cannabinoid%20CB2%20Receptor%20and%20Fatty%20Acid%20Amide%20Hydrolase&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Intranuovo,%20Francesca&rft.date=2023-01-12&rft.volume=66&rft.issue=1&rft.spage=235&rft.epage=250&rft.pages=235-250&rft.issn=0022-2623&rft.eissn=1520-4804&rft_id=info:doi/10.1021/acs.jmedchem.2c01084&rft_dat=%3Cproquest_cross%3E2757054448%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a348t-f369fbff044b387d8dc4103b99fb4efa3b02b0d9732707ce57f5cb28ce0720983%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2757054448&rft_id=info:pmid/36542836&rfr_iscdi=true